Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Dwyer

Showing results (211-220 of 260) with videos related to

Pageof 26
Sort By:
ACS Medicinal Chemistry Letters|August 22, 2018
Structure-Guided Design and Procognitive Assessment of a Potent and Selective Phosphodiesterase 2A InhibitorShawn J Stachel, Richard Berger, Ashley B Nomland, et al.
Biopolymers|October 17, 2007
Structure-guided discovery of cyclin-dependent kinase inhibitorsThierry O Fischmann, Alan Hruza, José S Duca, et al.
Hypertension (Dallas, Tex. : 1979)|May 2, 2018
Impact of Intensive Versus Standard Blood Pressure Management by Tertiles of Blood Pressure in SPRINT (Systolic Blood Pressure Intervention Trial)Brian P Shapiro, Walter T Ambrosius, Joseph L Blackshear, et al.
BMJ Open|May 28, 2016
Effectiveness of a biopsychosocial e-learning intervention on the clinical judgements of medical students and GP trainees regarding future risk of disability in patients with chronic lower back pain: study protocol for a randomised controlled trialChristopher P Dwyer, Hannah Durand, Pádraig MacNeela, et al.
Bioorganic & Medicinal Chemistry|March 5, 2014
The identification of novel 5'-amino gemcitabine analogs as potent RRM1 inhibitorsMarc A Labroli, Michael P Dwyer, Ruichao Shen, et al.
Molecular Cancer Therapeutics|July 29, 2010
Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitorDavid Parry, Timothy Guzi, Frances Shanahan, et al.
Pain Medicine (Malden, Mass.)|December 18, 2019
Effects of Biopsychosocial Education on the Clinical Judgments of Medical Students and GP Trainees Regarding Future Risk of Disability in Chronic Lower Back Pain: A Randomized Control TrialChristopher P Dwyer, Pádraig MacNeela, Hannah Durand, et al.
Bioorganic & Medicinal Chemistry Letters|June 16, 2009
Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide regionCynthia Aki, Jianping Chao, Johan A Ferreira, et al.
Journal of the American Society of Nephrology : JASN|August 16, 2024
Vascular Endothelial Growth Factor-B Blockade with CSL346 in Diabetic Kidney Disease: A Phase 2A Randomized Controlled TrialMelisa Cooper, David Z I Cherney, Tom H Greene, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 11, 2015
The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical TrialPeter N Van Buren, Julia B Lewis, Jamie P Dwyer, et al.
Pageof 26

Showing results (211-220 of 260) with videos related to

Sort By:
Pageof 26
ACS Medicinal Chemistry Letters|August 22, 2018
Structure-Guided Design and Procognitive Assessment of a Potent and Selective Phosphodiesterase 2A InhibitorShawn J Stachel, Richard Berger, Ashley B Nomland, et al.
Biopolymers|October 17, 2007
Structure-guided discovery of cyclin-dependent kinase inhibitorsThierry O Fischmann, Alan Hruza, José S Duca, et al.
Hypertension (Dallas, Tex. : 1979)|May 2, 2018
Impact of Intensive Versus Standard Blood Pressure Management by Tertiles of Blood Pressure in SPRINT (Systolic Blood Pressure Intervention Trial)Brian P Shapiro, Walter T Ambrosius, Joseph L Blackshear, et al.
BMJ Open|May 28, 2016
Effectiveness of a biopsychosocial e-learning intervention on the clinical judgements of medical students and GP trainees regarding future risk of disability in patients with chronic lower back pain: study protocol for a randomised controlled trialChristopher P Dwyer, Hannah Durand, Pádraig MacNeela, et al.
Bioorganic & Medicinal Chemistry|March 5, 2014
The identification of novel 5'-amino gemcitabine analogs as potent RRM1 inhibitorsMarc A Labroli, Michael P Dwyer, Ruichao Shen, et al.
Molecular Cancer Therapeutics|July 29, 2010
Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitorDavid Parry, Timothy Guzi, Frances Shanahan, et al.
Pain Medicine (Malden, Mass.)|December 18, 2019
Effects of Biopsychosocial Education on the Clinical Judgments of Medical Students and GP Trainees Regarding Future Risk of Disability in Chronic Lower Back Pain: A Randomized Control TrialChristopher P Dwyer, Pádraig MacNeela, Hannah Durand, et al.
Bioorganic & Medicinal Chemistry Letters|June 16, 2009
Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide regionCynthia Aki, Jianping Chao, Johan A Ferreira, et al.
Journal of the American Society of Nephrology : JASN|August 16, 2024
Vascular Endothelial Growth Factor-B Blockade with CSL346 in Diabetic Kidney Disease: A Phase 2A Randomized Controlled TrialMelisa Cooper, David Z I Cherney, Tom H Greene, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 11, 2015
The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical TrialPeter N Van Buren, Julia B Lewis, Jamie P Dwyer, et al.
Pageof 26